NanoViricides, Inc. NNVC
1.44
0.00
0.00%
as of 25 Sep
- Market cap
- $38.0M
- P/E
- 0.0×
Follow NNVC
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.28 | 1.06 | 4.43 | 3.17 |
Net Debt/EBITDA |
0.80 | 0.68 | 2.45 | 1.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.89 | 0.92 | 0.97 | |
Capex/Depreciation |
(0.06) | (0.63) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.11) | (0.10) | (0.10) | (0.09) | |
Cash per Share |
0.10 | 0.07 | 0.26 | 0.15 | |
Shareholders Equity per Share |
0.50 | 0.42 | 0.56 | 0.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.50 | 0.42 | 0.56 | 0.42 | |
Free Cash Flow |
(1.71) | (1.68) | (2.05) | (1.93) | |
Working Capital |
0.36 | 0.07 | 4.10 | 2.31 | |
Capital Expenditures |
(0.01) | (0.08) | 0.00 | 0.00 | |
Net Current Asset Value |
0.36 | 0.07 | 4.10 | 2.31 | |
| Other line items | |||||
Quick Ratio |
1.19 | 0.95 | 4.31 | 3.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.09) | (0.10) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.19 | 1.25 | 1.13 | 1.10 | |
Average Assets |
10.82 | 10.05 | 11.92 | 10.13 | |
Average Common Equity |
9.49 | 8.64 | 10.73 | 8.99 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates